The growth of the sterility testing market
can be attributed to the growth in the pharmaceutical and biotechnology
industries, increase in the number of new drug launches, and increasing
R&D in life science research.
According to the new market
research report sterility testing market is expected to reach USD 941.0
Million by 2021 from USD 528.0 Million in 2016, at a CAGR of 12.3% from
2016 to 2021.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=208866931
Major players in the
pharmaceutical sterility testing market include Merck KGaA (Germany),
Charles River Laboratories International, Inc. (U.S.), bioMérieux SA
(France), SGS S.A. (Switzerland), Sartorius AG (Germany), WuXi AppTec
(China), Nelson Laboratories (U.S.), Danaher Corporation (U.S.), Pacific
Biolabs (U.S.), Toxikon Corporation (U.S.), and Thermo Fisher
Scientific, Inc. (U.S.).
Merck KGaA (Germany) dominated the
sterility testing market in 2015. The company’s dominance in the market
can be attributed to its robust product portfolio and strong geographic
presence. The company focuses on organic as well as inorganic growth
strategies for enhancing its market position. In September 2016, the
company launched its Steritest Symbio Pump systems to enhance its
product portfolio and increase its market presence. Furthermore, the
company was focused on inorganic growth strategies. In November 2015,
Merck KGaA acquired Sigma-Aldrich Corporation (U.S.); this acquisition
helped the company strengthen its sterility testing product portfolio.
Charles
River Laboratories International, Inc. (U.S.) held the second position
in the sterility testing market in 2015. This can be attributed to the
company’s strong sterility testing portfolio. The company adopted
organic growth strategies such as mergers and acquisitions to boost its
market share. In November 2015, Charles River acquired Celsis
International Ltd. (U.S.). This acquisition helped the company to
strengthen its microbial detection product portfolio. Also in November
2015, Charles River Laboratories acquired Oncotest GmbH (Germany), a
global CRO dedicated to discovery services for oncology. This
acquisition strengthened Charles River’s portfolio of target discovery
& validation services and in vivo pharmacology.
bioMérieux SA
(France) held the third position in the sterility testing market in
2015. The company focuses on organic as well as inorganic growth
strategies such as expansions and collaborations to enhance its market
share. In March 2016, it entered into a distribution and co-development
strategic partnership with Copan Italia S.p.A. (Italy). According to the
terms of this agreement, bioMérieux SA and Copon will work together to
distribute and develop solutions for microbiology laboratory automation
and efficiency. Furthermore, the company was focused on organic growth
strategies. In Octamer 2014, bioMérieux opened a new diagnostic testing
facility in Isère, France. This facility enabled the company to develop
new diagnostic solutions related to microbiology.
SGS S.A. (Switzerland) held the fourth position in the
pharmaceutical sterility testing market in 2015. The company adopted
organic growth strategies such as expansions to boost its market share.
In September 2016, SGS opened a new facility in Wiesbaden, Germany. The
500-m2 facility will provide extractables and leachables (E&L)
testing to the pharmaceutical and related industries. This helped
company to expand its quality control release testing capabilities at
that facility. Also in December 2016, SGS acquired Quality Compliance
Laboratories Inc. (U.S.). This acquisition helped the company to provide
microbiological and analytical testing to pharmaceutical,
nutraceutical, and cosmeceutical industries.
Get Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=208866931
Based
on the analysis of strategic developments undertaken by market players
between 2013 and 2016, the key strategies followed by most companies in
the sterility testing market are expansions and
acquisitions. Some of the leading players that adopted this strategy
include bioMérieux SA (France), Merck KGaA (Germany), Nelson
Laboratories (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland),
Thermo Fisher Scientific, Inc. (U.S.), Charles River Laboratories
(U.S.), and WuXi AppTec (China).
